Update in systemic therapy of prostate cancer: improvement in quality and duration of life

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med.349(3), 215–224 (2003).
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Severson RK, Vaishampayan U, Hussain M. Survival analysis of distant prostate cancer by decade (1973–1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program registry: has outcome improved? (United States). Cancer Causes Control14(7), 681–685 (2003).
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer I. The effects of castration, of estrogen, and of androgen injection on serum phosphateases in metastatic carcinoma of the prostate. Cancer Res.1, 293 (1941).
   Google Scholar
• Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg.43, 209 (1941).
   Google Scholar
• Tannock IF, Osoba D, Stockler M et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone of symptomatic hormone resistant prostate cancer. A Canadian randomized trial with palliative endpoints. J. Clin. Oncol.14, 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol.17, 2506–2513 (1999).
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol.24(24), 3979–3983 (2006).
   PubMed Web of Science ®Google Scholar
• Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J. Clin. Oncol.25(Suppl. 18), 5015 (2007).
   Google Scholar
• Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology57(1), 127–132 (2001).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock I, DeWit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond G, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. 25(Suppl. 18), 5005 (2007) (Abstract 147)..
   Google Scholar
• Eisenberger MA, Crawford ED, Wolf M et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Semin. Oncol.21(5), 613–619 (1994).
   PubMed Web of Science ®Google Scholar
• Hussain M, Tangen CM, Higano C et al. Southwest Oncology Group trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group trial 9346 (INT-0162). J. Clin. Oncol.24(24), 3984–3990 (2006).
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol.21(7), 1232–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Ankerst DP, Caroline S et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl Cancer Inst.98(8), 516–521 (2006).
   PubMedGoogle Scholar
• Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol.25(25), 3965–3970 (2007).
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond G, De Wit R et al. Association of pain and quality of life response with PSA response and survival of patients with metastatic hormone refractory prostate cancer treated with docetaxel or mitoxantrone in the TAX327 study. J. Clin. Oncol.24 (Suppl.), (2006) (Abstract 4516).
   PubMedGoogle Scholar
• Graff J, Lalani AS, Lee S et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): results from the ASCENT trial. J. Clin. Oncol.25(Suppl. 18), 5074 (2007).
   Google Scholar
• Moreno J, DeBono JS, Shaffer D et al. Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J. Clin. Oncol.25(Suppl. 18), 5016 (2007).
   Google Scholar
• Hershberger PA, Yu WD, Modzelewski RA et al. Calcitriol (1,25-dihydroxy- cholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res.7, 1043–1051 (2001).
   PubMed Web of Science ®Google Scholar
• Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol.21(1), 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol.25(6), 669–674 (2007).
   PubMed Web of Science ®Google Scholar
• Dahut WL, Gulley JL, Arlen PM et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol.22(13), 2532–2539 (2004).
   PubMed Web of Science ®Google Scholar
• Picus J, Halabi S, Rini B et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Presented at: 2003 ASCO Annual Meeting (2003) (Abstract 1578).
   Google Scholar
• Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin. Cancer Res.13(4), 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized Phase III trial. J. Clin. Oncol.25(Suppl. 18), 5019 (2007).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24, 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor – secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res.13(13), 3883–3891 (2007).
   PubMed Web of Science ®Google Scholar
• Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin. Cancer Res.8(5), 962–966 (2002).
   PubMed Web of Science ®Google Scholar
• Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin. Oncol.20(3 Suppl. 2), 38–43 (1993).
   PubMedGoogle Scholar
• Porter AT, McEwan AJ, Powe JE et al. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.25(5), 805–813 (1993).
   PubMed Web of Science ®Google Scholar
• Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer88(12 Suppl.), 2934–2939 (2000).
   PubMedGoogle Scholar
• Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/ prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol.21(17), 3335–3342 (2003).
   PubMed Web of Science ®Google Scholar
• Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer. JAMA285, 2053–2055 (2000).
   Google Scholar
• Jones GW, Mettlin C, Murphy GP et al. Patterns of care of carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J. Am. Coll. Surg.180, 545–554 (1995).
   PubMedGoogle Scholar
• Gibbons RP, Correa RJ, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostate cancer long term results. J. Urol.141, 564–566 (1989).
   PubMedGoogle Scholar
• Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy: long term results. J. Urol.152, 1781–1785 (1994).
   PubMedGoogle Scholar
• Ohori M, Wheeler TM, Dunn JK et al. Pathological features in prognosis of prostate cancer detectable with current diagnostic tests. J. Urol.152, 1714–1720 (1994).
   PubMed Web of Science ®Google Scholar
• Partin A, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol.150, 110–114 (1993).
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Padraig W et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med.337, 295–300 (1997).
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med.341, 1781–1788 (1999).
   PubMed Web of Science ®Google Scholar
• The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br. J. Urol.79, 235–246 (1997).
   PubMedGoogle Scholar
• AJCC Cancer Staging Handbook. Fleming ID, Cooper JS, Henson DE et al. (Eds). Lippincott Raven, PA, USA, 203–208 (1998).
   Google Scholar
• Vicini FA, Horwitz EM, Gonzalez J, Martinez AA. Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J. Urol.158, 319–325 (1997).
   PubMedGoogle Scholar
• Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Am.20, 713–725 (1993).
   PubMed Web of Science ®Google Scholar
• Epstein J, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer71, 3582–3593 (1994).
   Google Scholar
• Anscher MS, Prosnitz LP. Multivariate analysis of factors predicting local relapse after radical prostatectomy: possible indications for postoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.21, 941–947 (1991).
   PubMedGoogle Scholar
• Ohori M, Wheeler TM, Kattan MW et al. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol.154, 1818–1824 (1995).
   PubMed Web of Science ®Google Scholar
• Mukamel E, deKernion JB, Dorey F et al. The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma of the prostate. Cancer59, 1535–1538 (1987).
   PubMed Web of Science ®Google Scholar
• Villers AA, McNeal JE, Redwine EA et al. Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J. Urol.143, 1183–1187 (1990).
   PubMed Web of Science ®Google Scholar
• Hanks GE, Buzydlowski J, Sause WT et al. Ten year outcomes for pathologic node-positive patients treated in RTOG 75–06. Int. J. Rad. Oncol. Biol. Phys.40, 765–768 (1998).
   PubMedGoogle Scholar
• Kattan MW, Eatham JA, Stapleton AM et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst.90(10), 766–771 (1998).
   PubMed Web of Science ®Google Scholar
• Perrapato SD, Carothers GG, Maatman TJ et al. Comparing clinical staging plus transrectal ultrasound with surgical-pathologic staging of prostate cancer. Urology33, 103–105 (1989).
   PubMedGoogle Scholar
• D’Amico AV, Schnall M, Whittington R et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology51, 449–454 (1998).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malcowicz SB et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome following radical prostatectomy for men with clinically localized prostate cancer. J. Urol.164, 759–763 (2000).
   PubMedGoogle Scholar
• Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol.145(2), 313–318 (1991).
   PubMed Web of Science ®Google Scholar
• Sun H, Sloan A, Mangner TJ et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur. J. Nucl. Med. Mol. Imaging32(1), 15–22 (2005).
   PubMedGoogle Scholar
• Powell IJ Jr, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J. Urol.168(5), 2016–2019 (2002).
   PubMedGoogle Scholar
• Bonney WW, Schned AR, Timberlake DS. Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end-points and meta-analysis of randomized trials. J. Urol.160, 1754–1760 (1998).
   PubMedGoogle Scholar
• Thompson I, Tangen C, Paradelo J et al. adjuvant radiotherapy for pathologically advanced prostate cancer. JAMA296, 2329–2335 (2006).
   PubMed Web of Science ®Google Scholar
• Bolla M, van Tienhoven G, de Reijke TM et al. EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT – results of the randomized EORTC Phase III trial 22961. J. Clin. Oncol.25(Suppl. 18), 5014 (2007).
   Google Scholar
• Ditonno P, Battaglia M, Selvaggi FP. Adjuvant hormone therapy after radical prostatectomy: indications and results. Tumori83, 567–575 (1997).
   PubMedGoogle Scholar
• Shipley WU, Lu JD, Pilepich MV et al. Effect of a short course of neoadjuvant hormone therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int. J. Radiat. Oncol. Biol. Phys.54(5), 1302 (2002).
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton C et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. long-term results of Phase III RTOG study 85–31. Int. J. Radiat. Oncol. Biol. Phys.57(Suppl. 2), S172–S173 (2003).
   PubMedGoogle Scholar
• Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J. Clin. Oncol.21(21), 3972–3978 (2003).
   PubMed Web of Science ®Google Scholar
• See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol.168(2), 429–435 (2002).
   PubMed Web of Science ®Google Scholar
• Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur. Urol.32(Suppl. 3), 81–85 (1997).
   PubMedGoogle Scholar
• Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. Br. J. Urol.86, 675–80 (2000).
   Google Scholar
• Glode LM, Hussain MH, Benson MC et al. SWOG 9921 – a Phase III multi-institutional trial of adjuvant therapy for high risk prostate cancer after radical prostatectomy. Presented at: Proc ASCO Prostate Cancer Symposium (2007) (Abstract 349)..
   Google Scholar
• Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol.18, 1050–1057 (2000).
   PubMed Web of Science ®Google Scholar
• Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a Phase I/II study. J. Urol.171(2 Pt 1), 709–713 (2004).
   PubMed Web of Science ®Google Scholar
• Hussain M, Smith DC, El-Rayes BF et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology61(4), 774–780 (2003).
   PubMed Web of Science ®Google Scholar